Search

Search Results

• P032 | IMPROVEMENT IN DEPRESSIVE AND ANXIETY SYMPTOMS DURING EPTINEZUMAB TREATMENT: A POST-HOC ANALYSIS FROM THE TACHIS STUDY

  E.M. Piella¹, A.M. Chiarandon¹, V. Batti¹, D.A. Montisano², L. F. Iannone³, C. Fasano⁴, G. Sebastianelli⁵, G. Coppola⁵, D. Ferrandi⁶, C. Lanni⁷, M.P. Prudenzano⁸, M. De Tommaso⁹, P. Merlo¹⁰, A. Viganò¹⁰, F. De Cesaris¹¹, A. Chiarugi¹¹, A. Munafò¹¹, F. Pistoia¹², R. Ornello¹², S. Sacco¹², A. Doretti¹³, L. Grazzi², F. Lo Castro¹⁴, R. Allamprese¹⁴, R. De Icco^15|16, G. Vaghi^15|16, C. Tassorelli^15|16, G. Avino¹⁷, M. Romozzi¹⁸, C. Vollono¹⁸, P. Calabresi¹⁸, S. Battistini¹⁹, A. Rufa¹⁹, M. Albanese²⁰, M. Trimboli²¹, G. Carlucci⁴, M. Silvestro²², A. Russo²², M. Valente²³, L. Fofi²⁴, M. Marcosano²⁴, P. Geppetti²⁵, C. Altamura²⁴, F. Vernieri²⁴, E. Rubino¹, I. Rainero¹, S. Guerzoni¹⁴ | ¹Department of Neuroscience “Rita Levi Montalcini”, University of Turin, Italy; ²Headache Center, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy; ³Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Italy; ⁴NEUROFARBA Department, University of Florence - Neurologia, AOU Careggi, Italy; ⁵Sapienza University of Rome, Department of Medico-Surgical Sciences and Biotechnologies, Polo Pontino, Latina, Italy; ⁶AOU Alessandria, SC Neurologia, Italy; ⁷Psicologia AOU Alessandria, Italy; ⁸Clinica Neurologica "L. Amaducci", Azienda Ospedaliero-Universitaria Consorziale di Bari, Italy; ⁹Neurophysiopathology Unit, Department of Translational Biomedicine and Neuroscience, University of Bari Aldo Moro, Italy; ¹⁰UO di Neurologia, Humanitas Gavazzeni, Bergamo, Italy; ¹¹Headache center and Clinical pharmacology unit, AOU Careggi, Florence, Italy; ¹²Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Italy; ¹³Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milano, Italy; ¹⁴Digital and Predictive Medicine, Pharmacology, Clinical Metabolic Toxicology-Headache Center and Drug Abuse, Laboratory of Clinical Pharmacology and Pharmacogenomics, AOU Policlinico, Modena, Italy; ¹⁵Department of Brain and Behavioral Sciences, University of Pavia, Italy; ¹⁶Headache Science and Neurorehabilitation Unit, IRCCS Mondino Foundation, Pavia, Italy; ¹⁷SOC Neurologia, Ospedale di Prato, Italy; ¹⁸Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Roma, Italy; ¹⁹Department of Medical, Surgical and Neurological Sciences, University of Siena, Italy; ²⁰Unit of Neurology, Department of Systems Medicine, University of Rome Tor Vergata, Italy; ²¹Headache Center, Unit of Neurology, AOU Renato Dulbecco, Catanzaro, Italy; ²²Inter-departmental Program of Headache Medicine and Primary Pain Syndromes, Department of Advanced Medical and Surgical Sciences, University of Campania “Luigi Vanvitelli”, Naples, Italy; ²³DMED, University of Udine and Clinical Neurology, Udine University Hospital, Italy; ²⁴Fondazione Policlinico Universitario Campus Bio-Medico, Roma e Università Campus Bio-Medico di Roma, Italy; ²⁵Department of Molecular Pathobiology and Pain Research Center, College of Dentistry, New York University, NY, USA

  03-11-2026

  DOI https://doi.org/10.4081/cc.2026.15988

  • 0 abstract views
  • 0 PDF

• P083 | EFFECT OF ATOGEPANT ON COGNITIVE FUNCTION FOLLOWING ACUTE TREATMENT OF MIGRAINE ACROSS MULTIPLE ATTACKS: RESULTS FROM THE ECLIPSE TRIAL

  R. Masselli¹, A. Van Dycke­­², G. Ahmadyar³, E. Brand-Schieber³, C. Castro³, R. Ornello⁴, L. Luo³, P. Pozo-Rosich^5|6, U. Reuter^7|8, K. Carr³, R. Gil-Gouveia^9|10 | ¹AbbVie Srl, Rome, Italy; ²Department of Neurology, General Hospital Sint-Jan Bruges, Belgium; ³AbbVie Inc. North Chicago, IL, USA; ⁴Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Italy; ⁵Headache Unit, Neurology Department, Vall d'Hebron University Hospital, Barcelona, Spain; Headache and Neurological Pain Research; ⁶Headache and Neurological Pain Research Group, Vall d'Hebron Institute of Research, Universitat Autonoma de Barcelona, Spain; ⁷University Hospital Bonn, Germany; ⁸Charité Universitätsmedizin Berlin, Germany; ⁹Neurology Department, Hospital da Luz, Lisboa, Portugal; ¹⁰Center for Interdisciplinary Research in Health, Universidade Católica Portuguesa, Lisboa, Portugal

  03-11-2026

  DOI https://doi.org/10.4081/cc.2026.16039

  • 0 abstract views
  • 0 PDF

• OC11 | A CASE REPORT OF GALCANEZUMAB-INDUCED MYASTENIA GRAVIS-LIKE SYMPTOMS

  F. Lo Castro, D. Brovia, S. Guerzoni | Digital and Predictive Medicine, Pharmacology and Clinical Metabolic Toxicology-Headache Center and Drug Abuse-Laboratory of Clinical Pharmacology and Pharmacogenomics, AOU Policlinico di Modena, Italy

  03-11-2026

  DOI https://doi.org/10.4081/cc.2026.15949

  • 0 abstract views
  • 0 PDF

• OC18 | LONG-TERM EFFECTIVENESS, SAFETY AND TOLERABILITY OF ATOGEPANT IN THE PREVENTION OF MIGRAINE: A MULTICENTRIC, PROSPECTIVE OBSERVATIONAL, REAL WORLD STUDY (THE 48-WEEK STAR STUDY)

  F. Vernieri^1|2, L. Francesco Iannone³, M. Marcosano^1|2, L. Fofi¹, F. Lo Castro⁴, G. Sebastianelli⁵, F. De Santis⁶, M. Corrado⁷, R. Ornello⁶, L. Grazzi⁸, D. Antonio Montisano⁸, F. De Cesaris⁹, A. Munafò⁹, G. Avino¹⁰, M. Trimboli¹¹, M. Albanese¹², A. Russo¹³, M. Silvestro¹³, G. Dalla Volta¹⁴, M. Romozzi¹⁵, P. Calabresi¹⁵, A. Boccalini⁴, P. Merlo¹⁶, M. Pia Prudenzano¹⁷, M. Rosaria Valente¹⁸, I. Rainero¹⁹, G. Giuliani²⁰, M. Altieri²⁰, A. Doretti²¹, G. Vaghi^7|22, F. Pistoia⁶, D. Ferrandi²³, S. Battistini²⁴, G. Coppola⁵, S. Guerzoni⁴, S. Sacco^6|25, C. Tassorelli^7|22, C. Altamura^1|2 | ¹Headache and Neurosonology Unit, Fondazione Policlinico Universitario Campus Bio-Medico, Roma, Italy; ²Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, Italy; ³Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Italy; ⁴Digital and Predictive Medicine, Pharmacology and Clinical Metabolic Toxicology-Headache Center and Drug Abuse-Laboratory of Clinical Pharmacology and Pharmacogenomics, AOU Policlinico Di Modena, Italy; ⁵Sapienza University of Rome, Department of Medico-Surgical Sciences and Biotechnologies, Polo Pontino, Latina, Italy; ⁶Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, Italy; ⁷Headache Science and Neurorehabilitation Centre, IRCCS Mondino Foundation, Pavia, Italy; ⁸Headache Center IRCCS Fondazione Istituto Neurologico "Carlo Besta", Italy; ⁹Headache center and clinical pharmacology, AOU Careggi, Firenze, Italy; ¹⁰Neurology Unit, Ospedale Santo Stefano, USL Toscana Centro, Prato, Italy; ¹¹Azienda Ospedaliera-universitaria "Renato Dulbecco", Catanzaro, Italy; ¹²Department of Systems Medicine, University of Rome Tor Vergata, Italy; ¹³Headache Center, Department of Medical, Surgical, Neurological, Metabolic and Aging Sciences, Second University of Naples, Italy; ¹⁴U.O Neurologia, Istituto Clinico Città di Brescia, Gruppo San Donato, Italy; ¹⁵Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Roma, Italy; ¹⁶UO di Neurologia, Humanitas Gavazzeni, Bergamo, Italy; ¹⁷Clinica Neurologica "L. Amaducci", Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari, Italy; ¹⁸Clinica Neurologica ASUFC, Dipartimento di Medicina DMED Università di Udine, Italy; ¹⁹Headache Center, Department of Neuroscience, University of Torino, Italy; ²⁰Department of Human Neuroscience, Sapienza University of Rome, Italy; ²¹IRCCS Istituto Auxologico Italiano, Milano, Italy; ²²Department of Brain and Behavioural Sciences, University of Pavia, Italy; ²³SC Neurologia, Azienda Ospedaliero Universitaria Santi Antonio e Biagio, Alessandria, Italy; ²⁴Department of Medical, Surgical and Neurological Sciences, University of Siena, Italy; ²⁵Neurology and Stroke Unit, ASL 1 Abruzzo, Avezzano-Sulmona-L’Aquila, Italy

  03-11-2026

  DOI https://doi.org/10.4081/cc.2026.15956

  • 0 abstract views
  • 0 PDF